ACRV
Acrivon Therapeutics, Inc.
2.00$
-1.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | – | – | – | – | +16.1% | +15.8% | +4.3% | +1.0% | -6.6% | +12.2% | -55.0% | +50.3% | -10.7% | +50.0% | +1.0% | +2.6% | -3.5% | +0.0% | -403.7% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -142.0% | – | – | |
| – | – | – | +37.8% | +97.3% | -32.3% | +94.8% | -26.2% | +66.5% | +7.8% | -2.4% | +49.3% | -26.6% | +33.6% | +25.6% | -2.8% | -15.9% | +5.0% | -15.7% | +10.2% | -1.7% | -6.4% | – | |
| – | – | – | +167.5% | -6.0% | +61.5% | -11.6% | +150.0% | +13.5% | +7.9% | +17.4% | -5.0% | +11.1% | +3.5% | -2.1% | +0.8% | -1.2% | +3.5% | -6.6% | -11.1% | -11.8% | +1.9% | – | |
| – | – | – | +59.9% | +63.7% | -15.2% | +61.6% | +3.9% | +44.7% | +7.8% | +4.0% | +29.5% | -16.6% | +22.9% | +17.3% | -1.9% | -13.4% | +4.7% | -11.9% | +6.8% | -7.2% | -4.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -89.0% | +1,212.5% | +259.0% | +169.5% | +61.1% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -89.0% | -1,412.5% | – | – | – | – | -2,023.4% | – | -89.8% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.